Restart Life Sciences Corp.
NMLSF
$0.07
-$0.01-14.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 96.80K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.80K | -- | -- | -- | -- |
| Cost of Revenue | 52.20K | -- | -- | -- | -- |
| Gross Profit | 44.50K | -- | -- | -- | -- |
| SG&A Expenses | 717.20K | 917.30K | 899.50K | 865.20K | 813.50K |
| Depreciation & Amortization | 3.80K | 1.20K | 1.30K | 1.40K | 1.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 776.90K | 922.10K | 904.40K | 870.20K | 818.60K |
| Operating Income | -680.20K | -922.10K | -904.40K | -870.20K | -818.60K |
| Income Before Tax | -647.60K | -983.60K | -870.70K | -380.60K | -299.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.65 | -0.98 | -0.87 | -0.38 | -0.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -647.60K | -983.60K | -870.70K | -380.60K | -299.70K |
| EBIT | -680.20K | -922.10K | -904.40K | -870.20K | -818.60K |
| EBITDA | -678.20K | -920.70K | -902.90K | -868.60K | -816.90K |
| EPS Basic | -0.02 | -0.03 | -0.03 | 0.00 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.02 | -0.04 | -0.04 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 165.28M | 135.49M | 112.88M | 91.82M | 73.04M |
| Average Diluted Shares Outstanding | 165.28M | 135.49M | 114.71M | 94.14M | 75.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |